Knowing when a machine learning system is not confident about its prediction is crucial in medical domains where safety is critical. Ideally, a machine learning algorithm should make a prediction only when it is highly certain about its competency, and refer the case to physicians otherwise. In this paper, we investigate how Bayesian deep learning can improve the performance of the machine–physician team in the skin lesion classification task. We used the publicly available HAM10000 dataset, which includes samples from seven common skin lesion categories: Melanoma (MEL), Melanocytic Nevi (NV), Basal Cell Carcinoma (BCC), Actinic Keratoses and Intraepithelial Carcinoma (AKIEC), Benign Keratosis (BKL), Dermatofibroma (DF), and Vascular (VASC) lesions. Our experimental results show that Bayesian deep networks can boost the diagnostic performance of the standard DenseNet-169 model from 81.35% to 83.59% without incurring additional parameters or heavy computation. More importantly, a hybrid physician–machine workflow reaches a classification accuracy of while only referring of the cases to physicians. The findings are expected to generalize to other medical diagnosis applications. We believe that the availability of risk-aware machine learning methods will enable a wider adoption of machine learning technology in clinical settings.
Mapping biological processes in brain tissues requires piecing together numerous histological observations of multiple tissue samples. We present a direct method that generates readouts for a comprehensive panel of biomarkers from serial whole-brain slices, characterizing all major brain cell types, at scales ranging from subcellular compartments, individual cells, local multi-cellular niches, to whole-brain regions from each slice. We use iterative cycles of optimized 10-plex immunostaining with 10-color epifluorescence imaging to accumulate highly enriched image datasets from individual whole-brain slices, from which seamless signal-corrected mosaics are reconstructed. Specific fluorescent signals of interest are isolated computationally, rejecting autofluorescence, imaging noise, cross-channel bleed-through, and cross-labeling. Reliable large-scale cell detection and segmentation are achieved using deep neural networks. Cell phenotyping is performed by analyzing unique biomarker combinations over appropriate subcellular compartments. This approach can accelerate pre-clinical drug evaluation and system-level brain histology studies by simultaneously profiling multiple biological processes in their native anatomical context.
Allogeneic T-cell therapies have the potential to improve both the efficacy and accessibility of life-changing cellular therapeutics. However, before this new paradigm can be fully established, there remains a need for improved manufacturing workflows to enable consistent production of highly efficacious allogeneic T-cell therapies. One of the core components of these workflows is the media used for the expansion of healthy donor T cells. In particular, a medium that can rapidly facilitate high levels of T-cell proliferation, maintain the desired central memory T (TCM) phenotype, and increase immune responses by enhancing the production of cytokines such as interferon gamma (INFγ) is a much-needed solution. Gibco™ CTS™ OpTmizer™ Pro Serum-free Medium (SFM), a novel medium formulated for allogeneic workflows, has been developed to meet this need. The following article details the potential of CTS OpTmizer Pro SFM to improve both workflow efficiency and overall therapeutic efficacy.